Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s blockbuster Wegovy medicine to treat a serious fatty liver disease. Shares in Novo Nordisk rose as much as 5% in early European trading Monday,

"Improving access to our authentic FDA-approved treatments is central to our mission at Novo Nordisk," said Novo Nordisk's executive vice president Dave Moore in a statement.

“While Ozempic is well covered in the US, let’s not forget that there are some patients who pay out-of-pocket for this vital medicine,” Dave Moore, executive vice president, of Novo Nordisk’s U.S. op...

The move comes as President Trump is pressuring drugmakers to lower drug costs.